Rifampicin-based tuberculosis (TB) treatment alters efavirenz (EFV) clearance. Polymorphisms in important drug metabolizing enzymes and the implications for EFV dosing were investigated.
Methods
Trough EFV concentrations (C were measured min) in 54 South African black patients. During TB treatment, EFV dose was 600 mg in patients <50 kg or 800 mg if ≥50 kg. Off TB treatment it was 600 mg. Polymorphisms in CYP2B6, CYP2A6 and UGT2B7 enzymes were sequenced. A multivariate generalized estimating equations model was fitted to assess predictors of high median EFV C. min
Results
During TB treatment, median EFV C was 3.2 min (IQR 2.6–6.3) μg/ml and 3.3 (2.4-9.5) μg/ml in the 800 mg and 600 mg groups, respectively. After TB treatment EFV C was 2.0 (1.4-3.5) μg/ml. Minor allele min frequencies for CYP2B6 516G→T, 785A→G, 983T→C, UGT2B7-372G→A, CYP2A6*9B and CYP2A6*17 were 0.31, 0.33, 0.23, 0.29, 0.10 and 0.02, respectively. Haplotypes CYP2B6*6 and CYP2B6*18 were found in 38.9% and 25.9% of patients, respectively. Polymorphisms in all three CYP2B6 genes studied (516T-785G-983C) were present in 11.1% of patients and in this group median EFV Cmin was 19.2 (IQR 9.5–20) μg/ml during and 4.7 (IQR 3.5–5.6) μg/ml after TB treatment. The presence of TB treatment and composite genotypes CYP2B6 516 GT/TT, CYP2B6 983 TC/CC and CYP2A6*9B carrier status predicted median EFV Cmin>4 μg/ml. Adverse events due to high EFV concentrations were rare.
Conclusions
Because polymorphisms of EFV metabolizing enzymes are frequent and are associated with elevated EFV concentrations in this population, EFV dose increases are unnecessary when concomitant rifampicin-containing TB treatment is prescribed.
PozniakA.L., CoyneK.M., MillerR.F.British HIV Association guidelines for the treatment of TB/HIV coinfection 2011.HIV Med2011; 12: 517–524.
3.
López-CortésL.F., Ruiz-ValderasR., VicianaP.Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.Clin Pharmacokinet2002; 41: 681–690.
4.
MatteelliA., RegazziM., VillaniP.Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients.Curr HIV Res2007; 5: 349–353.
5.
OrrellC., CohenK., ConradieF.Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?Antivir Ther2011; 16: 527–534.
6.
Brennan-BensonP., LyusR., HarrisonT., PakianathanM., MacallanD.Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all.AIDS2005; 19: 1541–1543.
7.
Lopez-CortesL.F., Ruiz-ValderasR., Ruiz-MoralesJ.Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.J Antimicrob Chemother2006; 58: 1017–1023.
8.
WardB.A., GorskiJ.C., JonesD.R.The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.J Pharmacol Exp Ther2003; 306: 287–300.
ChoD.Y., OgburnE.T., JonesD., DestaZ.Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.Antimicrob Agents Chemother2011; 55: 1504–1509.
11.
KwaraA., LarteyM., SagoeK.W., RzekN.L., CourtM.H.CYP2B6 (c.516G–>T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.Br J Clin Pharmacol2009; 67: 427–436.
12.
GyamfiM.A., FujiedaM., KiyotaniK., YamazakiH., KamatakiT.High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana.Eur J Clin Pharmacol2005; 60: 855–857.
13.
OgburnE.T., JonesD.R., MastersA.R.Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.Drug Metab Dispos2010; 38: 1218–1229.
14.
GengiahT.N., HolfordN.H., BothaJ.H.The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.Eur J Clin Pharmacol2012; 68: 689–695.
15.
MarzoliniC., TelentiA., DecosterdL.A.Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.AIDS2001; 15: 71–75.
16.
HofmannM.H., BlievernichtJ.K., KleinK.Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver.J Pharmacol Exp Ther2008; 325: 284–292.
17.
RamachandranG., Hemanth KumarA.K., RajasekaranS.CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.Antimicrob Agents Chemother2009; 53: 863–868.
18.
CohenK., GrantA., DandaraC.Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.Antivir Ther2009; 14: 687–695.
19.
UttayamakulS., LikanonsakulS., ManosuthiW.Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults.AIDS Res Ther2010; 7: 8.
20.
ManosuthiW., SukasemC., LueangniyomkulA.Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.Antimicrob Agents Chemother2013; 57: 1019–1024.
21.
KwaraA., LarteyM., SagoeK.W.Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.J Clin Pharmacol2008; 48: 1032–1040.
22.
McIlleronH.M., SchomakerM., RenY.Effects of rifampicin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.AIDS2013; 27: 1933–1940.
23.
BertrandJ., VerstuyftC., ChouM.Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.J Infect Dis2014; 209: 399–408.
24.
MutwaP.R., FillekesQ., MalgazM.Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms.J Acquir Immune Defic Syndr2012; 60: 400–404.
25.
ZangerU.M., KleinK.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance.Front Genet2013; 4: 24.
26.
HaasD.W., RibaudoH.J., KimR.B.Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.AIDS2004; 18: 2391–2400.
27.
NyakutiraC., RoshammarD., ChigutsaE.High prevalence of the CYP2B6 516G–>T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/ AIDS outpatients in Zimbabwe.Eur J Clin Pharmacol2008; 64: 357–365.
28.
MukonzoJ.K., RoshammarD., WaakoP.A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.Br J Clin Pharmacol2009; 68: 690–699.
29.
RotgerM., TegudeH., ColomboS.Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.Clin Pharmacol Ther2007; 81: 557–566.
30.
KwaraA., LarteyM., SagoeK.W., KenuE., CourtM.H.CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.AIDS2009; 23: 2101–2106.
31.
NgaimisiE., MugusiS., MinziO.Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.Clin Pharmacol Ther2011; 90: 406–413.
32.
SwartM., SkeltonM., RenY.High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.Pharmacogenet Genomics2013; 23: 415–427.
33.
SarfoF.S., ZhangY., EganD.Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.J Antimicrob Chemother2014; 69: 491–499.
34.
MehlotraR.K., BockarieM.J., ZimmermanP.A.CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment.Br J Clin Pharmacol2007; 64: 391–395.
35.
KwaraA., TashimaK.T., DumondJ.B.Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers.Antimicrob Agents Chemother2011; 55: 3527–3533.
36.
WangJ., SonnerborgA., RaneA.Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz.Pharmacogenet Genomics2006; 16: 191–198.
37.
MaimboM., KiyotaniK., MushirodaT., MasimirembwaC., NakamuraY.CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.Eur J Clin Pharmacol2012; 68: 267–271.
38.
ElensL., VandercamB., YombiJ.C.Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.Pharmacogenomics2010; 11: 1223–1234.
39.
HolzingerE.R., GradyB., RitchieM.D.Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.Pharmacogenet Genomics2012; 22: 858–867.
40.
KleinK., LangT., SausseleT.Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz.Pharmacogenet Genomics2005; 15: 861–873.
41.
MukonzoJ.K., OkweraA., NakasujjaN.Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.BMC Infect Dis2013; 13: 261.
42.
NgaimisiE., HabtewoldA., MinziO.Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.PLoS ONE2013; 8: e67946.
43.
LuetkemeyerA.F., RosenkranzS.L., LuD.Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.Clin Infect Dis2013; 57: 586–593.
44.
BorandL., MadecY., LaureillardD.Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA Trial).PLoS ONE2014; 9: e90350.
45.
BorandL., LaureillardD., MadecY.Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg.Antivir Ther2013; 18: 419–423.
46.
FriedlandG., KhooS., JackC., LallooU.Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.J Antimicrob Chemother2006; 58: 1299–1302.
47.
ManosuthiW., KiertiburanakulS., SungkanuparphS.Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.AIDS2006; 20: 131–132.
48.
RibaudoH.J., HaasD.W., TierneyC.Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.Clin Infect Dis2006; 42: 401–407.
49.
ENCORE1 Study Group, Puls R, Amin J, et al.Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.Lancet2014; 383: 1474–1482.
